Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts

Journal of Neuropathology and Experimental Neurology

Volumn 58, Issue 11, 1999, Pages 1170-1183

  Schmidt, Esther E ^a,b   Ichimura, Koichi ^a,b   Goike, Helena M ^b   Moshref, Ahmad ^b   Liu, Lu ^a,b   Collins, Peter V ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

Astrocytoma; Chromosome 10; DGGE; EGFR; Glioblastoma; Homozygous deletion

Indexed keywords

DNA; RNA;

ALLELE; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CHROMOSOME 10; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; XENOGRAFT;

EID: 0032757347     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199911000-00007     Document Type: Article

References (49)

1. Bigner SH, Mark J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 1988;48: 405-11
2. James CD, Carlbom E, Dumanski JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988;48:5546-51
3. Fults D, Pedone C. Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme. Genes Chromosom Cancer 1993;7:173-77
4. Karlbom AE, James CD, Boethius J, et al. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 1993;92:169-74
5. Rasheed BKA, McLendon RE, Friedman HS, et al. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25. Oncogene 1995;10:2243-46
6. Albarosa R, Colombo BM, Roz L, et al. Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet 1996;58:1260-67
7. Sonoda Y, Murakami Y, Tominaga T, Kayama T, Yoshimoto T, Sekiya T. Deletion mapping of chromosome 10 in human glioma. Jpn J Cancer Res 1996;87:363-67
8. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosom Cancer 1998;22:9-15
9. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [see comments]. Science 1997;275:1943-47
10. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 1997;15:356-62
11. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997;57:2124-29
12. Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 1997;94:9052-57
13. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57: 5221-25
14. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/ MMAC1 in primary breast carcinomas. Cancer Res 1997;57: 3657-59
15. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57: 4997-5000
16. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997;57:4710-13
17. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40
18. Guldberg P, Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997;57: 3660-63
19. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/ MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997;57:5254-57
20. Wang SI, Pue J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-86
21. Rasheed BK, Stenzel TT, McLendon RE, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 1997;57:4187-90
22. Bostrom J, Cobbers JM, Wolter M, et al. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998;58:29-33
23. Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G. PTEN/ MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 1998;16:541-45
24. Duerr EM, Rollbrocker B, Hayashi Y, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998;16:2259-64
25. Fults D, Pedone CA, Thompson GE, et al. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 1998;12:905-10
26. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet 1997;16:64-67
27. Nelen MR, van Staveren WC, Peeters EA, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-87
28. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998:7:507-15
29. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nature Genet 1998;19:348-55
30. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-78
31. Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 1997;94:12479-84
32. Cheney IW, Johnson DE, Vaillancourt MT, et al. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 1998;58:2331-34
33. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-17
34. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39
35. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72
36. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997;75:2-8
37. Liu L, Ichimura K, Pettersson EH, Collins VP. Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified. J Neuropathol Exp Neurol 1998;57:1138-45
38. Kleihues P, Burger PC, Scheithauer BW, Histological typing of tumors of the central nervous system., 2nd ed, World Health Organization. International histological classification of tumors, New York, Springer-Verlag, 1993
39. Collins VP. Cultured human glial and glioma cells. Int Rev Exp Pathol 1983;24:135-202
40. Dahia PLM, FitzGerald MG, Zhang X, et al. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 1998;16:2403-6
41. Olschwang S, Serova-Sinilnikova OM, Lenoir GM, Thomas G. PTEN germ-line mutations in juvenile polyposis coli. Nature Genet 1998;18:12-14
42. Yuvaniyama J, Denu JM, Dixon JE, Saper MA. Crystal structure of the dual specificity protein phosphatase VHR. Science 1996;272: 1328-31
43. Furnari FB, Huang HJS, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G(1) growth arrest in glioma cells. Cancer Res 1998;58:5002-8
44. Flint AJ, Tiganis T, Barford D, Tonks NK. Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc Natl Acad Sci USA 1997;94: 1680-5
45. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996;134:793-99
46. Davies MA, Lu YL, Sano T, et al. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 1998;58:5285-90
47. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-98
48. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-78
49. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 1998;95:13513-18